Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

Protagonist Therapeutics (NASDAQ:PTGX – Free Report) had its price objective hoisted by Truist Financial from $60.00 to $76.00 in a research note released on Tuesday morning,Benzinga reports. The firm ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...

BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $72 from $62 and keeps an Outperform rating on the shares.

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.